Sumitomo Pharma and Poxel Unveil Study Results of TWYMEEG® for Type 2 Diabetes

Sumitomo Pharma and Poxel have published preliminary results from the TWINKLE study, investigating TWYMEEG® for Japanese patients with type 2 diabetes and renal insufficiency. The study reveals a safety and tolerability profile consistent with previous studies.

Carried out open-label without a control group, this 52-week study involved 60 Japanese patients. The drug, administered in doses of 500 mg, showed serious adverse effects in 16.7% of cases but without a causal link.

These results prompt Sumitomo Pharma to discuss with Japanese authorities to potentially revise the drug's package insert for patients with an eGFR below 45 ml/min/1.73m² by fiscal year 2024.